BUSULPHAN-MELPHALAN VERSUS CARBOPLATIN-ETOPOSIDE-MELPHALAN CONDITIONING REGIMEN IN CHILDREN WITH NEUROBLASTOMA UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION

被引：0
|
作者：
Atas, E. [1 ]
Kesik, V. [1 ]
Babacan, O. [1 ]
Korkmazer, N. [2 ]
机构：
[1] Gulhane Mil Med Acad, Dept Pediat Oncol, Ankara, Turkey
[2] Gulhane Mil Med Acad, Dept Pediat, Ankara, Turkey
来源：
BONE MARROW TRANSPLANTATION | 2014年 / 49卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
PH-P219
引用
收藏
页码：S206 / S206
页数：1
相关论文
共 50 条
  • [31] High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma
    谷景立
    China Medical Abstracts(Internal Medicine), 2019, 36 (04) : 230 - 231
  • [32] Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database
    Desai, Ami V.
    Seif, Alix E.
    Li, Yimei
    Getz, Kelly
    Fisher, Brian T.
    Huang, Vera
    Mante, Adjoa
    Aplenc, Richard
    Bagatell, Rochelle
    PEDIATRIC BLOOD & CANCER, 2016, 63 (05) : 901 - 907
  • [33] Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patients
    del Giglio, A
    Costa, LJM
    Pinczowski, H
    Varella, PCS
    Luzzi, JR
    Neves, P
    Mota, A
    Boente, P
    Sampaio, C
    ACTA HAEMATOLOGICA, 1999, 102 (01) : 56 - 58
  • [34] High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma
    Sonata Jodele
    Christopher E. Dandoy
    Kasiani Myers
    Gregory Wallace
    Adam Lane
    Ashley Teusink-Cross
    Brian Weiss
    Stella M. Davies
    Bone Marrow Transplantation, 2018, 53 : 1311 - 1318
  • [35] High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma
    Jodele, Sonata
    Dandoy, Christopher E.
    Myers, Kasiani
    Wallace, Gregory
    Lane, Adam
    Teusink-Cross, Ashley
    Weiss, Brian
    Davies, Stella M.
    BONE MARROW TRANSPLANTATION, 2018, 53 (10) : 1311 - 1318
  • [36] High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma
    Hong, C. R.
    Kang, H. J.
    Kim, M. S.
    Ju, H. Y.
    Lee, J. W.
    Kim, H.
    Kim, H-S
    Park, S-H
    Park, K. D.
    Park, J. D.
    Shin, H. Y.
    Ahn, H. S.
    BONE MARROW TRANSPLANTATION, 2015, 50 (10) : 1375 - 1378
  • [37] High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma
    C R Hong
    H J Kang
    M S Kim
    H Y Ju
    J W Lee
    H Kim
    H-S Kim
    S-H Park
    K D Park
    J D Park
    H Y Shin
    H S Ahn
    Bone Marrow Transplantation, 2015, 50 : 1375 - 1378
  • [38] Mitoxantrone and melphalan as a conditioning regimen for autologous peripheral blood stem cell transplantation in adults with acute myelogenous leukemia
    Sprague, KA
    Padgaonkar, VA
    Klein, AK
    Chan, GW
    Miller, KB
    Klingemann, H
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 93 - 94
  • [39] Mitoxantrone and melphalan as conditioning regimen for autologous stem cell transplant for multiple myeloma.
    Beaven, Anne W.
    Comeau, Terrance
    Sharf, Andrew
    Moore, Dominic T.
    Serody, Jonathan
    Shea, Thomas C.
    Gabriel, Don A.
    BLOOD, 2006, 108 (11) : 834A - 834A
  • [40] Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM
    Saini, Neeraj
    Bashir, Qaiser
    Milton, Denai R.
    Tang, Guilin
    Delgado, Ruby
    Rondon, Gabriela
    Popat, Uday R.
    Hosing, Chitra M.
    Nieto, Yago
    Kebriaei, Partow
    Alousi, Amin M.
    Mehta, Rohtesh
    Srour, Samer
    Khouri, Issa F.
    Weber, Donna M.
    Thomas, Sheeba K.
    Lee, Hans C.
    Patel, Krina K.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD ADVANCES, 2020, 4 (19) : 4834 - 4837
12345